A 45-year-old woman is newly diagnosed with seropositive rheumatoid arthritis involving her metacarpophalangeal and proximal interphalangeal joints. According to standard clinical guidelines, arrange the following therapeutic interventions in the correct chronological sequence of escalation, starting from the initial medical management to the treatment of advanced, medically refractory disease.
- 1Initiation of a conventional synthetic DMARD (e.g., methotrexate)
- 2Addition of a biologic TNF inhibitor (e.g., adalimumab)
- 3Transitioning to a non-TNF biologic agent (e.g., rituximab)
- 4Referral for surgical joint reconstruction
Cevap
The correct sequence of therapy escalation for rheumatoid arthritis is: 1) Initiation of a conventional synthetic DMARD (methotrexate), 2) Addition of a biologic TNF inhibitor, 3) Transitioning to a non-TNF biologic agent, and 4) Referral for surgical joint reconstruction.
The standard paradigm for rheumatoid arthritis management follows a defined step-up approach. Treatment invariably begins with a conventional synthetic DMARD, almost exclusively methotrexate, which serves as the anchor drug. If the disease remains active after 3 to 6 months of optimized methotrexate, a biologic DMARD (usually a TNF inhibitor) is added to the regimen. If the patient has an inadequate response to the first biologic, guidelines suggest switching to a biologic with a different mechanism of action, such as a CD20 monoclonal antibody (rituximab) or an IL-6 inhibitor (tocilizumab). Finally, if all medical therapy fails and the patient develops end-stage structural joint destruction with intractable pain, surgical options such as arthroplasty or arthrodesis are pursued.
Adım Adım Çözüm
Anahtar Kavram
Step-up pharmacotherapy escalation in rheumatoid arthritis